-
New migraine favorite CGRP receptor antagonist Aimovig's sales are overtaken by Emgality
Time of Update: 2022-05-28
With the announcement of major companies' 2021 financial reports, the sales rankings of the above-mentioned CGRP receptor antagonists have also been released, as detailed in the table below .
-
Positive results from pivotal clinical trials of Biohaven and Pfizer's oral CGRP receptor antagonists
Time of Update: 2022-05-01
References:[1] Biohaven and Pfizer Announce Positive Topline Results of Pivotal Trial of Rimegepant for the Acute Treatment of Migraine in China and South Korea.
Retrieved February 14, 2022, from https:// and-pfizer-announce-positive-topline-results-of-pivotal-trial-of-rimegepant-for-the-acute-treatment-of-migraine-in-china-and-south-korea-301481322.
-
Express Delivers Positive Results from Pivotal Clinical Trial of Oral CGRP Receptor Antagonist for Migraine Patients in Asia Pacific
Time of Update: 2022-03-07
▎WuXi AppTec Content Team Editors On February 14, 2022, Biohaven Pharmaceutical and Pfizer announced positive top-line results from a Phase 3 clinical trial of rimegepant in adults with acute migraine .
-
Asia-Pacific Phase III BHV3000-310 Study Shows Oral Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist Provides Rapid and Durable Migraine Relief
Time of Update: 2022-03-02
Led by BioShin , the Phase 3 regional multicenter study BHV3000-310 met its co-primary endpoints evaluating the efficacy and safety of the oral calcitonin gene-related peptide ( CGRP ) receptor antagonist rimegepant orally disintegrating tablet ( ODT ) .
-
AbbVie's oral CGRP antagonist Qulipta receives FDA approval for preventive treatment of migraine
Time of Update: 2021-11-16
The results of the key phase 2b/3 trial of the drug showed that all three doses of Qulipta treatment group reached the primary efficacy endpoint of improvement from baseline in average migraine days during the 12-week treatment period, and the patient was compared with the baseline level of the placebo group.
-
More than half of patients reduce migraine days by 50%. Oral CGRP receptor antagonist shows preventive effect
Time of Update: 2021-09-13
AbbVie (AbbVie) recently announced that the results of its phase 3 clinical trial of the CGRP receptor inhibitor atogepant for the prevention of paroxysmal migraine patients have been published in the New England Journal of Medicine .
-
First oral CGRP-subject antagonist migraine drug! El Jian ubrogepant will submit a listing application in early 2019:
Time of Update: 2021-02-14
Allergan recently announced that it has completed two clinical studies of ubrogepant for acute migraine treatment and has obtained positive safety and tolerance data. first study (UBR-MD-04) assessed
-
Small molecule antagonists for migraine-prevention CGRP subjects are expected to be approved next year
Time of Update: 2020-11-07
Nurtec ODT, the first CGRP-subject antagonist with a rapidly dissolving agent, has been approved by the FDA for acute treatment of migraines in adults.
-
AbbVie's oral CGRP-subject antagonists reached the clinical end of Phase 3.
Time of Update: 2020-09-06
Atogepant is an oral-given CGRP-subject antagonist specifically developed for preventive treatment of migraines.
The number of seizures decreased by 50% in patients with more than half migraines, and AbbVie's oral CGRP-subject antagonists reached phase 3 clinical endpoints:
-
New migraine drug! AbbVie oral CGRP receptor antagonist atogepant prevention migraine Phase III clinical success!
Time of Update: 2020-08-06
data showed that all atogepant dose groups reached the primary endpoint and that the average number of migraine days per month was statistically significantly reduced compared to placebos.
-
The first nasal administration up to 2/3 of the main endpoint CGRP receptor antagonists can quickly relieve migraines
Time of Update: 2020-05-31
Migraines are the most common cause of severe headaches in the world People who experience frequent migraines may lose more than half of their normal lives as a result of migraines The disease robs pa
-
New medicine for acute migraine treatment! The oral CGRP receptor antagonist ubrogepant will be approved by FDA this month!
Time of Update: 2019-12-07
December 7, 2019 / BIOON / -- Allergan recently announced that the positive results of evaluating the application of ubrogepant in the phase III clinical study of acute treatment of adult migraine, ac
-
The first innovation in 25 years! The use of oral CGRP receptor antagonist ubrogepant in migraine treatment will be approved by FDA next month!
Time of Update: 2019-11-21
November 21, 2019 / BIOON / -- Allergan recently announced that the positive results of evaluating the application of ubrogepant in the phase III clinical study of adult migraine acute treatment aciev